Puma Biotechnology Inc - Common Stock (PBYI)

Competitors to Puma Biotechnology Inc - Common Stock (PBYI)

AstraZeneca plc

AstraZeneca is a global pharmaceutical giant that has a well-established oncology portfolio, including leading therapies for various types of cancer, enabling it to compete effectively with Puma Biotechnology. While Puma is small and focused on specific products like neratinib, AstraZeneca offers a range of commercially successful drugs backed by extensive research and development resources, alongside a robust network for distribution. This substantial infrastructure and financial power allows AstraZeneca to maintain a leading position within the cancer treatment market.

Blueprint Medicines Corporation 

Blueprint Medicines Corporation and Puma Biotechnology both aim to develop targeted therapies for genetic mutations in cancer. While Puma focuses on specific therapies like neratinib for breast cancer, Blueprint Medicines has carved out a niche in precision medicine, particularly with treatments for RET-altered cancers. Their emphasis on targeted genetic interventions gives them an advantage in ensuring their therapies address the specific needs of a subset of cancer patients, potentially leading to more effective treatments.

Iovance Biotherapeutics, Inc. 

Iovance Biotherapeutics specializes in cell therapy for cancer treatment, which sets it apart from Puma Biotechnology's small molecule approach. While both companies are in oncology, Iovance focuses on tumor-infiltrating lymphocyte therapy, aiming for a more personalized treatment strategy rather than the targeted therapies that Puma provides. Iovance’s unique cell therapy platform gives it a competitive advantage in terms of the burgeoning field of immunotherapy, which could drive significant interest and investment.

Mirati Therapeutics, Inc.

Mirati Therapeutics competes with Puma Biotechnology in the oncology sector, particularly with products targeting genetic alterations in tumors. Puma's neratinib is a well-established treatment for HER2-positive breast cancer, while Mirati is concentrating on therapies for KRAS mutations and other specific oncogenic drivers. Mirati's advanced capabilities in drug discovery and a focus on genetic mutations associated with various cancers provide significant leverage in gaining an edge in market presence and research advancements.

Zymeworks Inc.

Zymeworks, like Puma Biotechnology, focuses on developing innovative cancer therapies, particularly in the field of protein engineering and bispecific therapeutics. Both companies are working on solutions for oncology markets, leveraging their expertise in targeted therapies. However, Zymeworks is notable for its proprietary Zymeworks platform that allows for faster and more versatile development of biologic drugs, which provides it a competitive edge in terms of innovation and potential drug pipeline diversity.